Clinical trials
Locally Advanced clinical trials
Below are recruiting locally advanced clinical trials, each written for real people, not researchers. We’re tracking 971 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07202364RecruitingPhase 2
Study of YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
Changsha, HunanAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT05661461RecruitingPhase 1
Test drug dosing and safety for advanced cancers with liver issues
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
San Antonio, TexasAges 18 years+ - NCT07581912RecruitingPhase 2
Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hangzhou, ZhejiangAges 18–85 - NCT07288632Recruiting
Lung cancer gene test and blood clot risk study
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Perugia, PerugiaAges 18 years+ - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07487896RecruitingPhase 3
YL201 vs. chemo for advanced esophageal cancer after first treatment
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Anqing, AnhuiAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07028125RecruitingPhase 4
Digital symptom tracking for kidney cancer treatment
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
AnnecyAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+ - NCT05152472RecruitingPhase 2
Imatinib plus atezolizumab versus imatinib alone for advanced GIST
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Lyon, RhôneAges 18 years+ - NCT06353906RecruitingPhase 2
Chemo plus immunotherapy for advanced penile cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
LeuvenAges 18 years+ - NCT07633353Enrolling by invitation
Real-World Outcomes of a New Treatment for Advanced Kidney Cancer
This study looks at how well two newer cancer drugs (enfortumab vedotin and pembrolizumab) work together for advanced upper tract urothelial carcinoma—a rare kidney cancer. Researchers are collecting information from hospitals in France to understand how patients respond and what side effects occur in everyday care.
NîmesAges 18 years+ - NCT06028737RecruitingPhase 2/Phase 3
Chemotherapy before surgery for advanced stomach cancer
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
VilniusAges 18–80 - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Bullhead City, ArizonaAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Gilbert, ArizonaAges 18 years+ - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Fullerton, CaliforniaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+
Hear when a new Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced?
- Yes. Clin2 currently lists 971 recruiting locally advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.